Biogen (BIIB) faces a fluctuating market scenario with a host of activity around its business. The
FDA and
EMA have accepted its applications for
lecanemab-irmb for the treatment of early Alzheimer’s disease, and for higher dose SMA drug. The company's total liabilities have reached $11,954 mil.
Sage Therapeutics has acknowledged an unsolicited, non-binding acquisition proposal from Biogen, leading to a surge in Sage's stock. Meanwhile, Grimes & Company, Beacon Investment and ClearBridge Growth Strategy have sold Biogen shares, whereas Nisa Investment and Merit Financial Group have acquired more. CEO stated no urgent need for more acquisitions. Also, Biogen's Q4 earning estimates have been released by Wedbush, indicating potential value for long-term investors. The company completed the acquisition of
Human Immunology Biosciences, expanding its immunology portfolio. Also remarkable is the top-line phase 2 outcome of
SAGE-324, which is being developed to treat Essential Tremor. However, the company has seen a decline of 21.4% in the stock market in the last three months, despite signs of growth from its Alzheimer’s drug, Leqembi.
Biogen BIIB News Analytics from Mon, 04 Mar 2024 08:00:00 GMT to Sun, 26 Jan 2025 00:58:29 GMT -
Rating 2
- Innovation 7
- Information 6
- Rumor -3
